ITB vs XBI
iShares US Home Construction ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.37% for ITB.
- • ITB pays a higher dividend yield (1.36%).
Side-by-side metrics
| Metric | ITB | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.37% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.36% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $2.37B | $10.92B |
YTD return | 4.51% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.46 | 1.01 |
P/E ratio | 15.67 | — |
Last price | $94.85 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
ITB top holdings
| DHI | D.R. Horton Inc | 17.94% |
| PHM | PulteGroup Inc | 11.29% |
| LEN | Lennar Corp Class A | 8.13% |
| NVR | NVR Inc | 7.28% |
| TOL | Toll Brothers Inc | 4.72% |
| HD | The Home Depot Inc | 4.51% |
| LOW | Lowe's Companies Inc | 4.47% |
| SHW | Sherwin-Williams Co | 4.41% |
| MAS | Masco Corp | 3.43% |
| IBP | Installed Building Products Inc | 2.45% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About ITB
ITB (iShares US Home Construction ETF) is US homebuilding and construction companies. Managed by iShares, the fund carries $2.4B in assets under management, an expense ratio of 0.37%, a dividend yield of 1.36%. Its largest holding is D.R. Horton Inc (DHI), which represents 17.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.